By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Low-risk MDS had many exciting updates, starting with…
Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center Live report from ASCO23, Chicago, IL June 6, 2023 …
Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center Live report from ASCO23, Chicago, IL June 6, 2023 …
Palbociclib after progression on Palbociclib in HR-positive HER2-negative breast cancer does not show improvement in progression-free survival By Dr.…
By Dr. Arya Miriam Roy & Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center The CDK 4/6 inhibitors…
By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the…
On May 19, 2023, Epcoritamab-bysp (Epkinly, Genmab US, Inc) was granted accelerated approval by the US FDA for the treatment…
Dr. Richa Parikh interviewed Dr. Shaji Kumar of Mayo Clinic about his recommendations for the treatment of myeloma.
On May 22, 2023, the U.S. Food and Drug Administration approved avapritinib (Ayvakit) for the treatment of adults with indolent…
By Dr. Chepsy Philip Believer's Church Medical College Hospital Myeloproliferative - Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the…